Cambrio’s proposed acquisition of Penn lapses because of abandoned floatation

 | Print

Download

Cambridge-based biotechnology company Cambrio yesterday abandoned its proposed £20m-£22m floatation because of lack of interest from investors. It means that its £10m acquisition of the Welsh drugs company Penn lapses, although it may be renegotiated.

  • Financial Times 31/7/96 page